Peripheral neuropathy
Conditions
Interventions
Multiple myeloma
Peripheral neuropathy
Vitamin D
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: * Subjects are (newly) diagnosed with smoldering or symptomatic MM * Subjects must be over 18 years of age * Subjects must be able to give informed consent
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relationship between the occurrence of PN and the vitamin D status in MM patients. The main endpoint is the number of patients with neuropathy and the difference in neuropathy grading between patient groups with or without accurate vitamin D levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are to evaluate the influence of different vitamin D levels on the severity of PN; to search for differences in prevalence of PN for each drug; to determine the correspondence of the ICPNQ results and patients' records and to gain insight in the number of patients with inadequate 25-hydroxyvitamin D serum levels ( | — |
Countries
The Netherlands
Outcome results
None listed